IL6 and hepatocellular carcinoma: Although IL-6 acts as a double-edged sword, prolonged activation of the IL-6 signaling pathway during chronic liver diseases damages the liver and could ultimately result in liver carcinogenesis, as in HCC patients, elevated serum levels of IL-6 and the soluble IL-6R have been detected.132